Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11890643 | 0.85 | TLR8 (0.44) | TLR8HTTSMN1; SMN2IRAK4HDAC8 | |
| SCHEMBL30122249 | 0.82 | IRAK4 (0.41) | TLR8HTTIRAK4ALDH1A1MAPT | |
| SCHEMBL21810482 | 0.81 | TLR8 (0.36) | TLR8HTTSMN1; SMN2IRAK4HDAC8 | |
| SCHEMBL25339167 | 0.81 | TLR8 (0.36) | TLR8HDAC8 | |
| SCHEMBL25970033 | 0.81 | TLR8 (0.36) | TLR8HDAC8 | |
| SCHEMBL25339197 | 0.80 | TLR8 (0.31) | TLR8 | |
| SCHEMBL29041967 | 0.79 | IRAK4 (0.43) | TLR8HTTIRAK4NPC1ALDH1A1 | |
| SCHEMBL25339190 | 0.79 | TLR8 (0.40) | TLR8HTTIRAK4HDAC8NPC1 | |
| SCHEMBL20135108 | 0.79 | TLR8 (0.57) | TLR8HTTIRAK4 | |
| SCHEMBL25338343 | 0.78 | TLR8 (0.44) | TLR8HTTIRAK4HDAC8NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118973581-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12091411-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TLR8 20/4885HTT 2464/4885STAT3 145/4885 |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TLR8 20/4885HTT 2464/4885STAT3 145/4885 |
| US-12091411-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TLR8 20/4885HTT 2464/4885STAT3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.